Maitreya Medicare Ltd vs Vanta Bioscience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Maitreya Medicare Ltd is ₹ 125 as of 30 Oct 15:30 . The P/E Ratio of Maitreya Medicare Ltd changed from 30.8 on March 2024 to 0 on March 2026 . This represents a CAGR of -100.00% over 3 yearsThe P/E Ratio of Vanta Bioscience Ltd changed from 229.6 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 years The Market Cap of Maitreya Medicare Ltd changed from ₹ 80.63 crore on March 2024 to ₹ 121.19 crore on March 2026 . This represents a CAGR of 14.55% over 3 yearsThe Market Cap of Vanta Bioscience Ltd changed from ₹ 102.89 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The Dividend Payout of Maitreya Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Vanta Bioscience Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Maitreya Medicare Ltd

Maitreya Medicare Limited was originally incorporated as Maitreya Medicare Private Limited' at Surat Gujarat, vide a Certificate of Incorporation dated March 28, 2019, issued by the Registrar of Companies, Central Registration Centre (CRC).
Thereafter, name of the Company was changed to Maitreya Medicare Limited' and a fresh Certificate of Incorporation was issued by the RoC on March 30, 2023.
Since then, Company engages in providing healthcare services and products. The Company was founded by Dr. Narendra Singh Tanwar, an eminent and highly skilled cardiologist who has more than 20 years of experience in healthcare industry.
The Company is a growing organization that aims at strengthening and establishing itself as foremost healthcare services provider.
It has a team of medical practitioners who ensures that patients get the quality healthcare services.

About Vanta Bioscience Ltd

Vanta Bioscience Limited (VBS) was originally incorporated as a Private Limited Company on 29th April 2016 and was converted into a Public Limited Company with effect from 17th March 2017. VBS is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries.
In addition, Company provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product.
It also provides expert services for determination of health based exposure limits (e.

FAQs for the comparison of Maitreya Medicare Ltd and Vanta Bioscience Ltd

Which company has a larger market capitalization, Maitreya Medicare Ltd or Vanta Bioscience Ltd?

Market cap of Maitreya Medicare Ltd is 84 Cr while Market cap of Vanta Bioscience Ltd is 14 Cr

What are the key factors driving the stock performance of Maitreya Medicare Ltd and Vanta Bioscience Ltd?

The stock performance of Maitreya Medicare Ltd and Vanta Bioscience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Maitreya Medicare Ltd and Vanta Bioscience Ltd?

As of October 31, 2026, the Maitreya Medicare Ltd stock price is INR ₹125.0. On the other hand, Vanta Bioscience Ltd stock price is INR ₹20.39.

How do dividend payouts of Maitreya Medicare Ltd and Vanta Bioscience Ltd compare?

To compare the dividend payouts of Maitreya Medicare Ltd and Vanta Bioscience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.